[ Price : $8.95]
FDA resumes posting complete response letters just days after HHS confirmed that new rejection letter releases had been halted tem...[ Price : $8.95]
FDA approves a new subcutaneous formulation of Sanofi's anti-CD38 monoclonal antibody Sarclisa (isatuximab-irfc), allowing the the...[ Price : $8.95]
An FDA inspection of SGS North America's contract testing laboratory identifies significant concerns with the firms laboratory con...[ Price : $8.95]
FDA has expanded the indication for Merck's Keytruda (pembrolizumab), including its subcutaneous formulation Keytruda Qlex (pembro...[ Price : $8.95]
FDA grants Fast Track designation to Arialys Therapeutics ART5803 to treat anti-NMDA receptor encephalitis.[ Price : $8.95]
Referencing a Stat online report, MSN identifies three finalists to replace Marty Makary as FDA commissioner.[ Price : $8.95]
CDER and CBER continue to experience net workforce losses through the first nine months of fiscal year 2026, although hiring impro...[ Price : $8.95]
AstraZeneca and Ionis Pharmaceuticals say that their Phase 3 CARDIO-TTRansform trial evaluating Wainua (eplontersen) in patients w...